The European Hematology Association (EHA) is delighted to announce to the conference and meeting community the outcome of its Core PCO Invitation To Tender (ITT).

Barcelona, 9, February, 2022 – The EBMT and EHA are proud to announce the release of the first-ever open-access book on CAR-T cells to be officially launched during the EBMT-EHA…

The Hague, January 3, 2022  –EHA Congratulates seven talented researchers in Hematology on their receipt of an EHA Kick-Off Grant 2021 after a rigorous selection process.

Picture: Ineke Oostveen   On Sunday, November 21, 2021, Anneke Brand, MD, PhD, emeritus professor at Leiden University Medical Center (LUMC), passed away suddenly.

EHA Launches Digital Campaign In September 2021, the European Hematology Association (EHA) will honor Blood Cancer Awareness Month with an extensive digital campaign.

The Hague, 2 June 2021 –EHA congratulates nine talented researchers in hematology on their receipt of the EHA Research Grants 2021 after a rigorous selection process.

HemaSphere presents first in a series of Consensus Reports on Diagnosis of Inherited Bleeding Problems For hematologists, it can be challenging to make the correct diagnosis in patients with bleeding problems…

April 9, Brussels - The European Alliance for Personalised Medicine is holding its 7th annual presidency conference at the University Foundation in Brussels, and the event will include a session…

It is with great sadness that we announce the passing of Professor Michel Boiron last December 3. Boiron was the founding President (1992-1994) of the European Hematology Association (EHA).

Joint recommendations on diagnosis and treatment of CMML from two European specialty societies were published the December issue in HemaSphere, the official journal of the European Hematology Association (EHA).

The European Hematology Association (EHA) and European Society for Blood and Marrow Transplantation (EBMT) will hold the first European CAR T Cell Meeting together in Paris on February 14-16, 2019.

Two studies funded by EHA and published in the medical journal Lancet Haematology by a team of researchers from Oxford University and King’s College found that the economic burden of blood disorders (malignant and non-malignant) across the European Union, Iceland, Norway and Switzerland amounts to €23 billion per year.

The economic burden of blood disorders across the European Union, Iceland, Norway and Switzerland amounts to €23 billion per year.

Acute myeloid leukemia (AML) is an aggressive form of blood cancer in which the majority of cases express CD33 on the surface of the leukemia cells.

Most patients with acute myeloid leukemia (AML) can only be cured when a stem cell transplant induces an immune response against the patient’s leukemia.